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Isolation of a novel complement regulatory factor (GCRF) from
glomerular epithelial cells
RICHARD J. QUIGG
Division of Nephrology, Department of Internal Medicine, Medical College of Virginia, Richmond, Virginia, USA
Isolation of a novel complement regulatory factor (GCRF) from gb-
merular epithelial cells. Cultured rat glomerular epithelial cells (GEC)
are able to prevent both antibody-directed and spontaneous (alternative
pathway) complement activation. In this study, a novel complement
regulatory factor (GCRF) was isolated from GEC. The ability to
accelerate the decay of alternative pathway C3/C5 convertases formed
on sheep erythrocytes (EC3bBbP) was used to guide purification. GEC
were solubilized in Triton X-114 and GCRF was recovered in the
aqueous phase. Complement inhibitory material also was present in the
culture supernatant, which likely represented GCRF. By Mono Q anion
exchange chromatography, GCRF eluted at  0.6 sI NaC1 and by
Superose 6 size-exclusion chromatography, it had a Kay  0.3, GCRF
reduced the t11, of EC3bBbP from 128 minutes in buffer alone to 41
minutes in 3 pg/mI GCRF protein, and also prevented formation of
EC3bBbP in a dose-dependent fashion. Digestion with chondroitinase
ABC, neuraminidase, or trypsin, but not with heparitinase or chon-
droitinase AC significantly reduced the activity and size of GCRF,
demonstrating that it is a sialic acid-containing dermatan sulfate pro-
teoglycan. Thus, cultured rat GEC synthesize and secrete into the
medium, GCRF, a dermatan sulfate proteoglycan with complement
inhibitory activity.
Complement activation is regulated at several steps through-
out the cascades of the alternative and classical pathways. The
list of proteins that serve these regulatory functions continues
to grow. At the level of the C3 and CS convertases, these are the
fluid phase proteins, factor H [1] and C4 binding protein [2], and
the cell membrane proteins, C3b receptor (CR1) [3], decay
accelerating factor (DAF) [4], and membrane cofactor protein
[5]. With the exception of membrane cofactor protein, all
accelerate the decay of alternative and/or classical pathway C3
and CS convertases [61.
We previously have shown that cultured human glomerular
epithelial cells (GEC) express DAF on their surface which
limits antibody-directed complement activation [7]. We have
also demonstrated that cultured rat GEC have complement
inhibitory activity on their surface that is susceptible to proteo-
lytic enzyme digestion. The pattern of enzyme sensitivity was
consistent with known enzyme sensitivities of human DAF,
suggesting that rat GEC also express DAF, or a related protein
on their membrane [7]. Human GEC also express CR! [8], and
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Kasinath et al recently have identified this protein on the
surface of cultured rat GEC [9]. Hence, CR! may also play a
role in limiting complement activation on GEC.
The glomerular capillary wall, composed of a fenestrated
endothelial cell, the glomerular basement membrane, and the
GEC, functions as a size- and charge-restrictive filter of plasma
to form a largely protein-free urine [10]. An important compo-
nent of this filter are negatively charged proteoglycans com-
posed of a protein core and attached glycosaminoglycans,
heparan sulfate and chondroitin sulfates [11, 12]. GEC are
believed to be the major source of proteoglycans [13], which is
supported by recent studies showing that cultured human and
mouse GEC synthesize heparan and chondroitin sulfate proteo-
glycans and secrete them into the medium [14—16]. Besides their
role in maintaining the integrity of the glomerular capillary wall,
the function of glomerular proteoglycans is largely unknown,
although proteoglycans from other sites have been shown to
have a role in cell adhesion and in cell differentiation [17]. In
this study, the predominant complement inhibitory material
produced by cultured rat GEC was a dermatan sulfate proteo-
glycan, and not DAF or CR!. This proteoglycan, termed
GCRF, may limit complement activation in the glomerular
capillary wall and on the GEC surface in vivo.
Methods
Materials
Buffers used in hemolytic assays were: veronal buffered
saline (VBS, 145 m NaC1, 5 mrvi Na barbital, pH 7.4); half
isotonic VBS containing 2.5% dextrose, 0.1% gelatin, 0.15 mrs
CaC12, and 1 m MgC12 (DGVB); and, VBS containing 0.1%
gelatin and 10 mtvt EDTA (GVB-EDTA).
Chondroitinase ABC, chondroitinase AC, heparitinase,
Streptomyces hyaluronidase, neuraminidase (Type V), trypsin,
pronase (type XIV protease), Triton X-1 14, soybean trypsin
inhibitor, benzamidine, diisopropyl fluorophosphate (DFP),
phenylmethylsullonyl fluoride (PMSF), e-amino-n-caproic acid,
iodoacetamide, guanidine HC1, chondroitin sulfates A, B and C,
and heparan sulfate were from Sigma Chemical Co. (St. Louis,
Missouri, USA). Chondroitin sulfate B was from bovine mu-
cosa and contained 85% chondroitin sulfate B (dermatan
sulfate), the remainder being types A and C. [355]sulfate (43
Ci/mg 5, carrier free) was from ICN Biomedicals (Costa Mesa,
California, USA) and [4,5-3H]leucine (53 Ci/mmol) was from
New England Nuclear (Boston, Massachusetts, USA). Bio-Rex
70 was from Bio-Rad Laboratories (Richmond, California,
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USA), and Sephadex G-25 and G-50 (fine), Sepharose CL-4B,
and prepacked columns of Mono Q and Superose 6 were from
Pharmacia, Inc. (Piscattaway, New Jersey, USA).
Human C3 [18] and factor B [191 were purified according to
published methods. Human factors D and P were purchased
from Quidel (San Diego, California, USA). Rat C3 was purified
according to the method of Vranian, Conrad and Ruddy [20]
with minor modifications. Ninety ml of normal rat serum (NRS)
was fractionated with 5 to 12% polyethylene glycol and then
sequentially chromatographed on L-lysine-Sepharose, DEAE-
Sephacel, Sepharose CL-6B, and Sephacryl S-200 (Pharmacia).
C3 was purified 35-fold with a yield of 29.2mg as determined by
radial immunodiffusion. C3 activity was 93,000 U/mg, while the
activity of CS (the protein most likely to copurify with C3 [18])
was 3 U/mg.
GEC culture
Rat GEC were cultured on a collagen matrix (Vitrogen,
Collagen Corp., Palo Alto, California, USA) in Kl medium,
which is Dulbecco's Modified Eagle Medium (DMEM)/Ham's
Nutrient Mixture F-b (1:1) (GIBCO, Grand Island, New York,
USA), containing 5% Nu-Serum (Collaborative Research, Bed-
ford, Massachusetts, USA) and hormone supplements [211.
These cells have been previously characterized [21] and were
used between passages 13 and 35. Once cells were confluent in
100 mm culture dishes, the medium was removed, the cells
were washed twice with phosphate-buffered saline, pH 7.2
(PBS), and then removed with the adherent collagen, which was
digested with 0.1% collagenase (Type V, Sigma) for 30 minutes
at 37°C, following which GEC were washed extensively with
PBS. It should be noted that collagenase was necessary given
the collagen requirements of the GEC line, and the large volume
which the collagen occupies (3 to 4 ml per culture dish). It is
possible that cell surface proteins were digested by contaminat-
ing proteases within the collagenase preparation, however, as
the cells remained viable during collagenase treatment, intra-
cellular proteins should not have been affected.
For the majority of experiments, cells were maintained in Ki
medium until isolation. In one experiment, to evaluate comple-
ment inhibitory activity in the medium, nearly confluent cells in
five 100 mm culture dishes were cultured for 40 hours in
medium consisting of DMEM/Ham's F-b (1:1) with 0.4% fetal
call serum, following which the conditioned medium was har-
vested and any free cells removed by centrifugation. GEC
remained viable during this period, however, cell division was
markedly reduced [22].
Solubilization of GEC
Triton X-l 14 was used to solubilize GEC, because of its low
cloud point temperature [23]. With phase separation, the bulk of
proteins segregate into the aqueous phase, whereas integral
membrane proteins [23] and proteins linked via phosphatidyl-
inositol to the plasma membrane, such as DAF [24, 251, are
recovered in the lipid phase. The GEC pellet was solubilized in
100 mM NaCI, 20 mrvi bis-Tris, pH 6.0 (bis-Tris buffer) contain-
ing 10 mrvi EDTA, 10 mrvi iodoacetamide, 5 mM DFP, 1% Triton
X-1l4 (0.2 ml per culture dish) for 15 minutes on ice, followed
by centrifugation at 3750 rpm for 10 minutes at 4°C. The
supernatant was then warmed to 22°C (above the cloud point of
Triton X-ll4 [23]), and centrifuged for 10 minutes at 15,000
rpm. The aqueous phase appearing in the upper layer was
removed, and the lipid-rich pellet was reconstituted with the
solubilizing buffer without Triton X-l 14, and both were placed
on ice. From three separate isolations from 50 to 100 culture
dishes, the total recovery of protein (determined by the Pierce
BCA assay, Rockford, Illinois, USA) was 1.06 0.35 mg per
100 mm culture dish (mean SD) with 87.9 0.7% of protein
recovered in the aqueous phase.
Determination of complement inhibitory activity
The means to assess complement inhibitory activity was
based on the ability of collected fractions to decay complement
intermediates formed on sheep erythrocytes (E), as has been
used in the past to identify and purify complement regulatory
proteins [1, 3, 4]. In order to form alternative pathway C3/C5
convertases, rat C3b was bound via its free sulfhydryl group
[26] to sheep E with a heterobifunctional cross linking agent. E
at 2 x l09/mI in VBS were incubated with 2 mM sulfosuccin-
imidyl (4-iodoacetyl) aminobenzoate (sulfo-SIAB, Pierce) for 30
minutes at 37°C. C3b was generated from rat C3 (in some
experiments, where indicated, human C3 was used in an
identical fashion) by incubating C3 with trypsin at a 100:1 ratio
(wt:wt) for one minute at 37°C, following which a twofold molar
excess of soybean trypsin inhibitor was added. After washing,
E were resuspended at 4 x l09/ml and 500 tg/ml C3b was added
for 60 minutes at 37°C to form EC3b. Cells were then adjusted
to 5 x 107/ml, and sufficient B, D, and P were added for nine
minutes at 30°C to form EC3bBbP, such that if convertases
were decayed for 20 minutes in DGVB alone there was an
average of one hemolytic site per cell (z) [4], unless otherwise
noted. Cells were washed in DGVB and resuspended to 1 x
108/ml. One hundred pA of EC3bBbP was then added to an equal
volume of DGVB containing a 1/50 dilution of fractions to be
assessed for inhibitory activity. After 20 minutes at 30°C,
residual convertases were completed by addition of C3-C9 (300
pA of a 1/20 dilution of NRS in GVB-EDTA; NRS-EDTA) for 60
minutes at 37°C, and hemolysis determined. The capacity of the
samples to reduce hemolysis (that is, accelerate decay of
EC3bBbP) compared to buffer alone was calculated and ex-
pressed as percent z reduction [4].
The complement inhibitory effects of GCRF were character-
ized as follows. The time course of EC3bBbP inactivation was
determined by incubating EC3bBbP at 1 x 108/ml in DGVB +
with an equal volume of various concentrations of GCRF, or
buffer alone. After various times, 200 pA of cells were removed
and added to 300 pA NRS-EDTA for 60 minutes at 37°C, and
hemolysis determined. To determine whether GCRF could
affect EC3b prior to the formation of the alternative pathway
C3/C5 convertase (that is, before addition of B, D, and P), EC3b
at 1 x 108/ml were mixed with equal volumes of various
concentrations of GCRF for 30 minutes at 30°C. Samples were
then either used immediately or they were washed and resus-
pended to 5 x 107/ml, and B, D, and P added for nine minutes
at 30°C. The resultant EC3bBbP were then completed with
NRS-EDTA as before and hemolysis quantitated.
Studies with enzymes
To determine the nature of GCRF, digestion with different
enzymes were performed, followed by assessment of functional
activity and size. Seventy pA of GCRF was incubated with an
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equal volume of chondroitinase ABC (1 U/mi), chondroitinase
AC (1 U/ml), Streptomyces hyaiuronidase (100 U/mi), trypsin (1
mg/mi) in 50 mi NaCi, 50 mii Tris, pH 7.0, or heparitinase (5
U/mi) or neuraminidase (1 U/nil) in 100 m Na acetate, 10 mrvi
CaCl2, pH 7.0 for one hour at 37°C. In all incubations, except
for with trypsin, DFP was added to 5 mi. At the end of the
incubation, a twofold molar excess of soybean trypsin inhibitor
was added to the tube containing trypsin. The resulting digests
were then diluted 1/25 in DGVB and 100 d added to 100 pJ
EC3bBbP (1 x 108/ml). For these studies, human C3b was used
and the input of B, D, and P were adjusted so that after a 90
minute decay at 30°C in untreated GCRF (that is, exposed to
buffer alone), followed by addition of NRS-EDTA, z was 1.
In the case of chondroitinase ABC and neuraminidase, which
had an effect on GCRF (Results), additional digestions were
performed identically to those described above, however, in the
presence of 10 m benzamidine, 100 mM e-amino-n-caproic
acid, 10 m.'i iodoacetamide, 10 mri EDTA (chondroitinase ABC
only), and 5 mi DFP in an attempt to neutralize any unrecog-
nized protease activity in the enzyme preparations. To exclude
a direct effect of the enzyme on the assay, EC3b at I x 108/ml
were incubated for 90 minutes at 30°C with an equal volume of
a 1/25 dilution of 0.5 U/ml chondroitinase ABC or neuramini-
dase in the presence of the protease inhibitors. They were then
washed with DGVB and made EC3bBbP with B, D, and P,
as before. After washing, they were resuspended to 1 x 108/ml
in DGVB and decayed for 90 minutes at 30°C in an equal
volume of GCRF or buffer alone, following which residual
convertase sites were developed with NRS-EDTA.
The effect of enzymes on the size of GCRF was assessed by
size-exclusion chromatography on a Superose 6 column run in
50 niM NaCI, 50 mrt Tris, pH 7.0 using a Pharmacia FPLC
system. Parallel determinations were done on GCRF incubated
in enzyme inhibitors only.
Metabolic labelling of cells
GEC were labelled with [35S]sulfate and [3Hlleucine as fol-
lows. All incubations were done at 37°C in a humidified atmo-
sphere of 95% air/5% CO2. Nearly confluent GEC in two 100
mm cultures dishes were washed twice with Hanks' balanced
salt solution, and then incubated for three hours in K! medium
lacking leucine and MgSO4, prepared using powdered DMEM/
Ham's Nutrient mixture F-12 Base reconstituted with 2.5 mM
glutamine, 0.5 mM lysine, 0.12 mrvt methionine (all from Sigma),
1.05 mi CaCl2, and 0.7 mri MgC12, along with Nu-Serum which
had been dialyzed against PBS. Cells were again washed, and
then incubated for 15 hours in leucine- and MgSO4-free Kl
containing 25 iCi/ml {3Hlleucine and 100 CiIml [35S]sulfate (4
mllwell). The medium was harvested, free cells removed by
centrifugation, and the supernatant immediately placed on ice.
Cells were washed three times with Hanks' balanced salt
solution, and then incubated for 90 minutes in leucine- and
MgSO4-free KI medium to which 1 mM unlabelled leucine and
Na2SO4 had been added. Cells were washed, treated with
collagenase, washed extensively with PBS, and then solubilized
as described above. TCA precipitability of aqueous soluble 3H-
and 35S-labelled material was 98.2 and 54.4%, respectively.
Prior to use, both the medium and cell extract were passed over
a Sephadex G-25 column equilibrated in bis-Tris buffer to
remove free [35S]sulfate and [3H]leucine.
Size exclusion chromatography under dissociative conditiojis
The following studies were done in 4 M guanidine HC1, which
dissociates non-covalently bound proteins [271. Unlabelled
GCRF was isolated as described in Results, and 500 1 applied
to a Superose 6 column in 0.05 M Tris, 4 M guanidine HC1, pH
7.0 at 0.2 mllmin. One ml fractions were collected and 300 d
from each fraction was passed over a 3 ml column of Sephadex
G-25 in DGVB Collected fractions were diluted 1/3 and used
in the hemolytic assay for complement inhibition.
Additional studies were performed on GEC that were labelled
with [35S]sulfate and solubilized in Triton X-l 14 as described
above (unlabelled leucine was used in these experiments). The
aqueous phase was made 4 M with solid guanidine and then
exchanged into buffer consisting of 7 M urea, 0.02 M bis-Tris,
0.01 M EDTA, 0.1 mM PMSF, pH 6.0 by passage over a
Sephadex G-50 column. 35S-labelled GCRF was then isolated as
described in Results and 200 d was applied to a 118 x 0.9 cm
column of Sepharose CL-4B in 4 M guanidine HC1, 0.1 M
Na2SO4, 0.1 M Tris-HC1, 0.5% (vol/vol) Triton X-lOO [281. The
column was run at 3 mllhr and 1 ml fractions were collected and
assessed for radioactivity. The void and total volumes of the
column were determined with 3H-labelled hyaluronic acid (pro-
vided by M. Yanagishita and J.C. Calvo, National Institute of
Dental Research) and [35S}sulfate, respectively. Additional
labelled material was desalted on Sephadex G-25 in 0.05 M
Tris-HC1, pH 7.2, for determination of complement inhibitory
activity and for cellulose acetate electrophoresis.
Cellulose acetate electrophoresis
Glycosaminoglycans were isolated from GCRF either by
digestion of the protein core with 10 .tg/ml pronase for two
hours at 50°C (for 35S-labelled GCRF in 0.05 M Tris-HCI) or by
/3-elimination in 0.5 N NaOH for 24 hours at 4°C, followed by
neutralization with HC1 [27]. The resultant glycosaminoglycans
were precipitated with 4 vols of absolute ethanol, centrifuged
for 15 minutes at 8800 x g, and the pellet resuspended in 1/5 vol
water [291. Cellulose acetate electrophoresis was performed
using a Beckman Microzone Electrophoresis Cell (Palo Alto,
California, USA) in 0.2 M calcium acetate, pH 7.0, for two
hours at a constant current of S mA [29]. Five pi of GCRF
glycosaminoglycans were run in parallel with standards (1.25 g
each). To determine the enzyme sensitivity of the GCRF
glycosaminoglycans, incubations were performed in the pres-
ence of enzymes as described above. Cellulose acetate strips
were stained with 0.1% alcian blue in 0.1% acetic acid, followed
by destaining in 10% acetic acid [29]. In the case of 35S-labelled
GCRF, cellulose acetate strips were sprayed with En3Hance
spray (New England Nuclear), and then exposed for 7 to 10
days at —70°C to Kodak X-OMAT film (Eastman Kodak Co.,
Rochester, New York, USA).
Statistics
Data are expressed as mean SD. Comparisons were made
by two-tailed unpaired Student's t-test.
Results
Isolation of GCRF
Triton X-114 partitioning. Unexpectedly, there was no com-
plement inhibitory activity recovered in the lipid phase of
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Fig. 1. Mono Q chromatography of pass-through material from Bio-
Rex 70. Twenty ml was applied, followed by a NaC1 gradient from 0.1
to0.8 M. 0.5 ml fractions were collected and assessed for their ability to
decay EC3bBbP, and data expressed as percent z reduction compared
to control. Symbols are: (• •) % z reduction; (V----V) A280; (....)
NaC1 concentration.
60
Fig. 2. Superose 6 chromatography of GEC concentrate from Mono Q.
The bulk of complement inhibitory activity appeared at Kay 0.3.
Symbols are: (S 5) % z reduction; (V----V) A280.
Triton X-114 solubilized GEC, while there was substantial
activity in the aqueous phase (693 370 U/mg, where 1 U is the
reciprocal of the dilution of sample that resulted in a 30%
reduction in z compared to EC3bBbP in buffer alone [4]).
Chromato graphic purification. To remove potential contam-
inating CR1, a cation exchange step on Bio-Rex 70 [3, 30] in
bis-Tris buffer (pH 6.0) was performed on the aqueous soluble
GEC extract, and the pass-through material subsequently stud-
ied. Notably, protein eluted from Bio-Rex 70 with 0.5 M NaCl
had complement inhibitory activity (in one isolation, 11.6% of
total complement inhibitory activity was in this fraction, but
was not studied further), which possibly was CR1.
Pass-through material from Bio-Rex 70 was applied to a
Mono Q column equilibrated in bis-Tris buffer and then a linear
gradient of NaCI applied. As shown in Figure 1, the bulk of
complement inhibitory material appeared after 0.6 M NaCI.
Fractions 89 to 105 were pooled, diluted 2:1 with bis-Tris buffer,
and then reapplied to the Mono Q column. There was no
detectable pass-through protein and bound material was eluted
with bis-Tris buffer containing 1 M NaCI. Five hundred /Ll of the
concentrated material was applied at 0.2 mllmin to a Superose
I III Ii..
Fraction number
Fig. 3. Mono Q chromatography of GEC conditioned medium. After
50 ml of medium was applied, a 30 ml gradient from 0.1 to 1.0 M NaCl
was applied, and I ml fractions collected and tested for their ability to
decay EC3bBbP. Symbols are: (S 5) % z reduction; (V----V) A280;
(....) NaC1 concentration.
Time, minutes
Fig. 4. Effect of various concentrations of GCRF on the decay of
EC3bBbP. Symbols are: (0) zero; (A)O.75 zg/ml; (A) 1.5 g/ml; (5)3.0
pgIml.
6 column equilibrated in PBS, and 0.5 ml fractions collected. As
shown in Figure 2, the majority of complement inhibitory
activity had a Kay 0.3. The peak of activity (Kay  0.1) was
pooled and saved for further studies.
Conditioned medium. To determine whether GEC condi-
tioned medium contained complement inhibitory activity, 50 ml
of medium was acidified to pH 6.0, filtered, and then passed
over a Mono Q column. As with the solubilized cell extracts,
complement inhibitory activity predominantly appeared at
NaCl concentrations of  0.6 M (Fig. 3), suggesting that GEC
secreted GCRF into the medium.
Hemolytic studies
As shown in Figure 4, GCRF obtained from the Superose 6
column reduced the t112 of EC3bBbP in a dose-dependent
fashion. In buffer alone, the t112 of EC3bBbP was 128 mm,
which decreased to 74, 56, and 41 minutes in the presence of
0.75, 1.5, and 3.0 g/ml ofGCRFprotein, respectively. If EC3b
were preincubated with GCRF for 30 minutes, followed by
addition of B, D, and P to make functional C3/C5 convertases
(EC3bBbP), significant inhibition in hemolytic activity occurred
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Table 1. Effect of GCRF on EC3b
GCRF concentration
pg/ml
Z
Washed Unwashed
0 0.88 0.02 1.04 0.05
0.75 1.12 0.14 0.77 0.09
1.5 0.98 0.03 0.56 0.02"
3.0 0.94 0.02 0.44 0.04'
EC3b at 1 x 108/ml in DGVB were incubated for 30 mm at 30°C
with an equal volume of either buffer alone or varying concentrations of
GCRF. Cells were then either washed once and resuspended to 5 X
107/ml in DGVB, or used immediately. Factors B, D, and P were
added for 9 mm at 30°C to form alternative pathway C3/C5 convertases
(EC3bBbP), and convertase activity in 200 i1 samples determined by
addition of 300 d NRS-EDTA. After 60 mm at 37°C, cells were pelleted
and hemolysis determined by measuring hemoglobin in the supernatant
at 0D414. Data are expressed as the average number of hemolytic sites
per cell (z), and are the mean SD (N = 3).
a P < 0.02; b P < 0.001 compared to buffer alone
only if cells were not washed prior to addition of B, D, and P
(Table 1). These results show that GCRF can prevent alterna-
tive pathway C3/C5 convertase formation as well as accelerate
their decay, but it does not bind to E, either through membrane
binding (as DAF does [31]), binding to sulfo-SIAB on the E
surface, or through non-specific interactions, nor does it have
sufficient affinity for C3b on the surface of EC3b to remain after
washing.
Enzyme studies
GCRF isolation. For these studies, partially purified GCRF
was isolated as follows. The aqueous phase from Triton X-l 14
solubiized GEC (in general, from fifty 100 mm culture dishes)
was applied to a Mono Q column in bis-Tris buffer, and
subsequently a 10 ml gradient of NaCl applied to 0.6 M. The
concentration of NaCI was kept at 0.6 M for 6 ml and then raised
to 1 M. The majority of complement inhibitory activity was
recovered in the 1 M NaCl pool. Collected material was
neutralized with 1 M Tris base (1%, vollvol), and used for
subsequent studies.
Hemolytic assays. As shown in Table 2, GCRF isolated in
this manner was highly active on EC3bBbP formed with human
C3, in that a 1/25 dilution of GCRF incubated in enzyme
inhibitors alone (1:1), reduced z by 60% after 90 minutes (that
is, from 2.27 to 0.92). Trypsin treatment of GCRF nearly
completely eliminated its activity (Table 2), supporting that it is
a protein. Because GCRF was large and anionic as determined
by chromatography, consistent with the known characteristics
of proteoglycans synthesized by GEC [14—161, additional stud-
ies were performed with specific enzymes reactive with the
polysaccharide chains of these molecules [27]. Chondroitinase
ABC, but not chondroitinase AC, heparitinase, or Streptomy-
ces hyaluronidase, significantly reduced activity of GCRF (Ta-
ble 2), suggesting that it is a dermatan sulfate-containing pro-
teoglycan [271. Notably, treatment with neuraminidase also
significantly reduced 3CRF activity (Table 2), and thus, sialic
acid residues must be important for the functional integrity of
this molecule.
Although the chondroitinase ABC and neuraminidase prepa-
rations used in these studies had been tested and found to be
free of protease activity by the manufacturer, additional studies
Table 2. Effect of enzymes on GCRF
Enzyme GCRF Z
None + 0.92 0.04
Chondroitinase ABC + 1.98 0.38a
Chondroitinase AC + 0.99 0.03
Heparitinase + 0.93 0.05
Streptomyces hyaluronidase + 0.93 0.08
Neuraminidase + 1.68 005b.c
Trypsin + 1.87 0.05"°
None — 2.27 006b
GCRF was exposed to the various enzyme preparations listed for 60
mm at 37°C. All contained 5 mri DFP, except for trypsin, which was
neutralized after incubation with soybean trypsin inhibitor. One hun-
dred l EC3bBbP at 1 x l08/ml were incubated with 100 d of the
various digests (diluted 1/25) for 90 mm at 30°C, and resulting conver-
tase activity determined by addition of NRS-EDTA as before. Values
are mean 5D (N = 3).
P < 0.01; P < 0.001 compared to GCRF unexposed to enzymes;
C P < 0.001 compared to incubations in the absence of GCRF
were performed in the presence of protease inhibitors of dif-
ferent classes [27] (Methods) in addition to DFP used previ-
ously. After decay of EC3bBbP in GCRF exposed to enzyme
inhibitors alone, z was 1.02 0.11, while in the presence of
buffer alone (that is, an identical formulation as the first, only
lacking GCRF), z was 2.19 0.22 (N = 3; P < 0.002), again
illustrating the "decay-accelerating" activity of GCRF. Chon-
droitinase ABC inhibited GCRF activity in a dose-dependent
fashion, such that z was 2.20 0.75, 1.40 0.05, and 1.14
0.04, at enzyme concentrations of 0.5, 0.25, and 0.125 U/ml,
respectively. Neuraminidase at 0.5 U/ml also significantly in-
hibited GCRF activity (z 1.46 0.09; P < 0.01). Therefore,
these results support the conclusions that GCRF is a chon-
droitin (dermatan) sulfate proteoglycan containing sialic acid
residues.
To exclude a direct effect of the enzyme preparation on the
hemolytic assay, EC3b were preincubated with chondroitinase
ABC or neuraminidase at the concentrations used in the above
experiments, and then made EC3bBbP with B, D, and P, and
decayed for 90 minutes in GCRF. After a 90 minute decay, z
was 0.80 0.04, 0.83 0.10, and 0.73 0.06 in cells exposed
to neuraminidase, chondroitinase ABC, and protease inhibitors
alone, respectively (N 5; NS), indicating that the enzymes
alone did not reduce decay of EC3bBbP. Notably, higher
concentrations of neuraminidase (0.5 U/b9 EC3b), did mod-
estly increase susceptibility to NRS-EDTA after formation of
AP convertases and subsequent decay in DGVB (z 0.93
0.04 and 0.79 0.02, in cells exposed to neuraminidase or
buffer alone; N = 4; P < 0.001), presumably due to the removal
of sialic acid on the E membrane, which promotes the accessi-
bility of factor H (in NRS-EDTA) to EC3bBbP [32]. Again, in
these neuraminidase-treated cells, GCRF effectively decayed
EC3bBbP (z = 0.32 0.01).
Chondroitin sulfate B at 50 g/ml did not accelerate the decay
of EC3bBbP (made with human C3b) compared to buffer alone
(t112 = 43 and 42 mm, respectively; r = —0.99 for both), while
the t112 was 29 mm (r —0.97) in GCRF diluted 1/40 (by protein
assay 14 g/ml). Therefore, the decay accelerating activity of
GCRF was not a nonspecific effect of this glycosaminoglycan.
Size exclusion chromatography. As the majority of GCRF's
activity appeared at Kay  0.3 and several of the enzyme
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preparations had contaminating/carrier proteins that were
smaller, the data presented will be limited to Kay < 0.4.
Chondroitinase ABC and neuraminidase reduced the size of the
peak at Kay 0.02 as well as the protein appearing after this
peak (Fig. 5). Chondroitinase AC and heparitinase slightly
reduced the early peak compared to incubations in enzyme
inhibitor alone, however, they did not affect later appearing
protein (Fig. 5). Trypsin also reduced, but did not eliminate, the
early peak and subsequently appearing protein (not shown).
Therefore, the loss of activity of GCRF following treatment
with chondroitinase ABC, neuraminidase, and trypsin, was
associated with a reduction in its size.
35S and 3H labelling
GEC were labelled with [35S]sulfate and [3H]leucine for 15
hours, and the medium and cellular extract chromatographed
on Mono Q. As shown in Figures 6A and B, the predominant
appearance of 35S-labelled material late in the NaC1 gradient (
0.6 M) corresponded to activity in hemolytic assays (Figs. 1 and
3), providing further evidence that GCRF is a sulfated proteo-
glycan. In both the medium (Fig. 6B) and aqueous soluble cell
extract (Fig. 6A), the amount of 3H-labelled protein at  0.6 M
NaC1 was a relatively minor fraction of total protein.
Size exclusion chromatography with guanidine HC1
GCRF was isolated as described above, only instead of using
bis-Tris buffer containing 1 M NaC1 to elute GCRF from the
Mono Q column following the 0.6 M plateau, buffer containing
0.05 M Tris, 4 M guanidine HC1, pH 7.0 was used instead, to
eliminate non-covalent interactions between proteoglycans and
proteins [27]. GCRF was then run over a Superose 6 column
and fractions tested for hemolytic inhibitory activity. As shown
in Figure 7, three distinct peaks of activity were recovered at
Kay 0.03, 0.26, and 0.38, suggesting that GCRF is a heteroge-
neous molecule with three apparent species of different sizes.
Additional studies were done with the aqueous phase from
Triton X-1 14 solubilized 35S-labelled GEC that was made 4 M
guanidine. Following buffer exchange into 7 M urea, this was
applied to a Mono Qcolumn, a gradient of NaC1 was run to 0.6
M NaC1, and material remaining on the column eluted with 4 M
><
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Fig. 6. Mono Q chromatography of GEC (A) and GEC conditioned
medium (B) labelled with 135S]sulfate and [3H]leucine. Once loaded, a
25 ml gradient from 0.1 to 1.0 M NaC1 was run, and 0.5 ml(A) or 1.0 ml
(B) fractions collected, and 35S and 3H radioactivity determined.
Symbols are: (L----LJ) 3H-dpm/fraction; (S •) 35S-dpm/fraction;
(....) NaC1 concentration.
K
Fig. 7. Superose 6 chromatography of GCRF under dissociative con-
ditions in 4 M guanidine HCI. One ml fractions were collected, desalted
on a Sephadex G-25 column, and tested for their ability to decay
EC3bBbP. Symbols are: (S •) % z reduction; (V----V) A280.
guanidine HC1. Two hundred d, containing 4.6 x io dpm, was
then applied to a Sepharose CL-4B column. As shown in Figure
8, the main peak of 35S-labelled material appeared at Kay 0.54
(long arrow), although as with the Superose 6 column, there
were peaks of smaller size (Kay 0.61 and 0.67; small arrows).
The 35S-labelled material eluted from the Mono Qcolumn with
4 M guanidine HC1 inhibited EC3bBbP in a dose-dependent
fashion (r = —1.00 for z values vs. concentration), establishing
that GCRF was present in this preparation.
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Fig. 5. Superose 6 chromatography of GCRF following enzyme treat-
ment. Symbols are: (—'O) no enzyme; (L1----LJ) heparitinase; (A----A)
chondroitinase AC; (O—-—O) chondroitinase ABC; (V V) neuramin-
idase.
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Fig. 8. Sepharose CL-4B chromatography of 35S-labelled GCRF iso
lated under dissociative conditions.
Cellulose acetate electrophoresis
Glycosaminoglycans from 35S-labelled GCRF isolated under
dissociative conditions migrated to a single spot (Fig. 9A) with
a mobility similar to that of heparan sulfate standard (Fig. 9B).
However, chondroitinase ABC, but not heparitinase treatment
eliminated the 35S spot (not shown). As unknown glycosamin-
oglycans do not always migrate equivalently to standards [27],
enzyme sensitivity was necessary to establish the identity of the
GCRF glycosaminoglycan as being dermatan/chondroitin sul-
fate. Unlabelled GCRF glycosaminoglycan showed identical
mobility to the 35S-labelled GCRF isolated under dissociative
conditions (Fig. 10). As with labelled GCRF glycosaminogly-
can, heparitinase treatment had no effect, but notably, chon-
droitinase AC treatment eliminated this spot (Fig. 10), estab-
lishing that GCRF glycosaminoglycan contains glucuronic acid
residues [27].
Discussion
This study demonstrates that cultured rat GEC synthesize
and secrete into the medium a unique complement regulatory
factor, GCRF. That GCRF has complement inhibitory activity
is shown by its ability to accelerate the decay of preformed
alternative pathway C3/C5 convertases, and also prevent their
formation in a dose-dependent fashion. On the basis of its
susceptibility to chondroitinase ABC and trypsin digestion, it is
a proteoglycan. As digestion with heparitinase, chondroitinase
AC, or Streptomyces hyaluronidase did not affect its activity, it
appears to be a dermatan sulfate proteoglycan [27] . In meta-
bolic labelling studies, substantial 35S was incorporated into
macromolecules with the chromatographic characteristics of
GCRF, adding further support to its being a sulfated proteogly-
can.
As shown by cellulose acetate electrophoresis, chondroiti-
nase AC digested the glycosaminoglycans of GCRF, and there-
fore GCRF contains glucuronic acid residues; however, the
activity of GCRF was unaffected by chondroitinase AC, and
thus glucuronic acid may be unnecessary for its functional
activity on complement. Alternatively, chondroitinase AC may
not have the access to glucuronic acid in the intact GCRF that
it has in the isolated glycosaminoglycan. As dermatan sulfate
may contain more than half of its uronic acid residues as
÷
Fig. 9. Cellulose acetate electrophoresis of 35S-labelled GCRF iso-
lated under dissociative conditions. A is the autoradiogram, while B is
the same sheet stained with alcian blue to reveal the glycosaminoglycan
standards. The origins are indicated by the short arrow and the
direction of migration by the long arrow. CSA, chondroitin 4-sulfate;
CSB, dermatan sulfate; CSC, chondroitin 6-sulfate; HS, heparan sul-
fate.
glucuronic acid (the remainder being iduronic acid) [33], the
data presented in this study are consistent with the identifica-
tion of GCRF as a dermatan sulfate proteoglycan.
Dermatan sulfate glycosaminoglycans alone did not affect
alternative pathway C3/C5 convertases, suggesting either that
the dermatan sulfate glycosaminoglycans of GCRF have a
unique composition, or that the activity of GCRF is due to its
three dimensional configuration, which in the case of proteo-
glycans can be quite complex [34]. Notably, dermatan sulfate
proteoglycans may have higher affinity for proteins than other
proteoglycans (of equal charge density), perhaps due to their
spatial characteristics [34]. Support that the dermatan sulfate
glycosaminoglycans of GCRF themselves are not responsible
for complement inhibition comes from studies in which the
activity of GCRF was substantially reduced after digestion with
trypsin, which affects the protein core but not the glycosamino-
glycan side-chains. The core protein alone also appears to lack
I
LL
0.25 0.50
Kay
0.75
35S—GCRF
I
S
HS
• S csc
• Q CSB(DS)
CSA
Quigg: Glomerular complement regulatory factor 675
1
Fig. 10. Cellulose acetate electrophoresis of GCRFfollowing enzyme
digestion. GCRF was incubated with either heparitinase (GCRF +
HEP), chondroitinase AC (GCRF + CHOND), or no enzyme (GCRF).
Legends are the same as in Figure 9.
complement inhibitory activity, as digestion with chondroiti-
nase ABC led to complete loss of hemolytic inhibitory activity.
The significant decrease in GCRF's activity following neur-
aminidase digestion shows that sialic acids are important for its
activity. The reduction in size of GCRF by size-exclusion
chromatography (Fig. 5), suggests either that these sialic acids
are important for the spatial characteristics of GCRF and/or
that they occupy internal positions in the polysaccharide side
chains [35]. Alternatively, as size exclusion chromatography
was performed under non-dissociative conditions, sialic acids
may have led to adherence of (cationic) proteins or to self-
aggregation of proteoglycans [36].
The finding of a dermatan sulfate proteoglycan from GEC is
consistent with two recent studies on cultured human GEC by
Thomas et al [15] and by Klein Ct al [16]. In the latter study,
dermatan sulfate proteoglycan, identified by susceptibility to
chondroitinase ABC and relative insensitivity to chondroitinase
AC, was identified in both the culture medium and cell layer. By
anion exchange chromatography, it was the most negatively
charged of the proteoglycans, similar to what is described in
this study for GCRF. However, under dissociative conditions
on Sepharose CL-4B, it appeared as a broad peak centered
around Kay 0.27 [16], which is larger than GCRF (Kay 0.54).
Notably, in the study by Klein et al, unlike the other proteo-
glycans isolated, dermatan sulfate proteoglycan did not bind to
a hydrophobic affinity column [16], similar to the case with
GCRF (unpublished observations).
The exact mechanism of GCRF's action was not determined
in this study, although it acts similarly to the C3b binding
proteins, factor H, DAF, and CR1, in that it decays preformed
alternative pathway C3/C5 convertases [61. It has further simi-
larities to DAF in that it prevents the formation of these
convertases [6, 31], and it does not have high enough affinity for
C3b [5, 37] to allow its purification by C3b affinity chromatog-
raphy (unpublished observations). However, GCRF does not
incorporate into the E membrane as DAF does [31]. As sialic
acids are known to increase accessibility of factor H to cell-
bound C3b [32], one consideration is that GCRF was increasing
the access of factor H in NRS-EDTA to C3b on the E surface.
However, the fact that the t112 of EC3bBbP was decreased by
GCRF would suggest that its effect was directly on these
convertases rather than through a factor H "cofactor activity"
(that is, ifthe latter were the case, one would expect that the t112
would not be affected, but rather that the z reduction would be
constant at all time points).
Heparin, a highly sulfated glycosaminoglycan, inhibits sev-
eral steps of complement activation, including the formation of
EC3bBbP [38]. Heparin does not, however, accelerate the
decay of EC3bBbP [39], and the data presented here show that
dermatan sulfate glycosaminoglycan also does not enhance the
decay of this intermediate. Notably, squid cartilage chondroitin
sulfate E glycosaminoglycan accelerates the decay of EC3bBbP
(made with activated P) in addition to preventing its formation
[39]. Chondroitin sulfate E proteoglycan isolated from murine
bone marrow-derived mast cells also prevents the formation of
+ EC3bBbP; the ability of this proteoglycan to accelerate thedecay of EC3bBbP was not determined in this study, however
[39]. It appears as though chondroitin sulfate E and GCRF are
unrelated, given the ineffectiveness of GCRF glycosaminogly-
can to hasten the decay of EC3bBbP and that the uronic acid
residues in chondroitin sulfate E appear to be exclusively
glucuronic acid [39]. However, determination of the precise
uronic acid composition and the sulfation pattern of GCRF
requires additional study.
As proteoglycans are an integral component of the glomerular
basement membrane [10—13], the findings reported here may
have relevance in vivo. A complement regulatory factor in the
glomerular basement membrane and the subepithelial space
may be of particular importance, given the large size of the fluid
phase complement regulatory proteins, C4 binding protein (Mr
590 kD [2]) and factor H (although factor H has an Mr of 150
kD, it behaves as a molecule of 300 kD [1], presumably due to
its elongated asymmetric shape [40]), while the proteins of the
spontaneously active alternative pathway and the terminal
complement sequence have Mr 206 kD [41]. Because the
glomerular basement membrane acts to restrict passage of
proteins on the basis of size and charge [10], there may be
relative hindrance of these regulatory proteins, while the active
complement proteins should be more accessible to sites within
the glomerular basement membrane and on the GEC. Hence,
the elaboration of a complement regulatory factor by GEC may
restrict complement activation that otherwise might occur in
the glomerular capillary wall. The lack of high affinity of GCRF
for C3b may be important to prevent C3b from accumulating in
the glomerular basement membrane. It remains to be seen
whether GCRF is like DAF, in having a much higher affinity for
the active bimolecular complex of C3bBb, than either protein
alone [37], thereby allowing it to be a "selective" complement
inhibitor.
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